Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Med Hypotheses
; 64(6): 1162-5, 2005.
Article
en En
| MEDLINE
| ID: mdl-15823708
ABSTRACT
Recently, cyclooxygenase-2 (COX-2) inhibitor therapy has emerged as a possible new approach to the prevention and treatment of colorectal cancer (CRC). The COX enzymes (COX-1 and COX-2) are key enzymes of prostaglandin (PG) biosynthesis and are overexpressed in approximately 80% of human CRCs. Presumably, bioactive lipid products of COX, such as PGE(2), are responsible for some of the pro-neoplastic effects mediated by this enzyme. The early effects of COX-2-derived PGE(2) are in part mediated by the epidermal growth factor receptor (EGFR). Selenomethionine decreases COX-2 protein and PGE(2) levels. Cetuximab is a chimeric IgG1 monoclonal antibody that binds to EGFR with high specificity thus blocking ligand-induced phosphorylation of EGFR. Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory CRC. We suggest that selenium supplementation by decreasing the COX-2 protein and PGE-2 levels in cancer cells may increase efficacy of cetuximab in advanced CRC patients.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Selenio
/
Neoplasias Colorrectales
/
Adenocarcinoma
/
Inhibidores de la Ciclooxigenasa
/
Anticarcinógenos
/
Receptores ErbB
/
Anticuerpos Monoclonales
/
Proteínas de Neoplasias
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Med Hypotheses
Año:
2005
Tipo del documento:
Article
País de afiliación:
Turquía